Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.68 USD
Change Today +0.07 / 2.68%
Volume 826.1K
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Open
$2.52
Previous Close
$2.61
Day High
$2.84
Day Low
$2.51
52 Week High
07/28/15 - $4.10
52 Week Low
08/24/15 - $1.38
Market Cap
79.8M
Average Volume 10 Days
915.5K
EPS TTM
$-0.96
Shares Outstanding
29.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOGENEX PHARMACEUTICAL INC (OGXI)

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

35 Employees
Last Reported Date: 03/26/15

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $497.2K
Chief Financial Officer and Vice President
Total Annual Compensation: $138.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $413.2K
Compensation as of Fiscal Year 2014.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

OncoGenex Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's revenue decreased to $4.0 million from $4.9 million a year ago. Net loss was $6.0 million, or $0.26 per diluted common share compared with $7.0 million, or $0.47 per diluted common share for the three months ended June 30, 2014. Loss from operations was $5,587,000 against $7,630,000 a year ago. For the six months, the company's revenue decreased to $5.4 million from $16.7 million a year ago. Net loss was $10.5 million, or $0.46 per diluted common share compared with $15.7 million, or $1.05 per diluted common share for the three months ended June 30, 2014. Loss from operations was $10,583,000.

OncoGenex Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 13, 2015

OncoGenex Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 13, 2015

OncoGenex Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 13, 2015

OncoGenex Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.68 USD +0.07

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit www.oncogenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.